ARRY Financial Facts
License and milestone revenue: 18.46MWeighted average shares outstanding - diluted (in shares): 57.03M
See Full Income Statement
Accumulated other comprehesive income (loss): -1K
Total current assets: 82.07M
See Full Balance Sheet
Array BioPharma, Inc. (ARRY) Earnings
|
Expand Research on ARRY
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +31.7% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +9.5% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/10/22 | Q222 | N/A | $0.02 | N/A | N/A | $336.55M | N/A | N/A | N/A | ||
| 5/10/22 |  |
Q122 | $0.02 | -$0.06 | +$0.08 | $300.6M | $271.6M | N/A |  | | Details |
| 4/5/22 | |
Q421 | -$0.06 | -$0.03 | -$0.03 | $219.9M | $213.82M | N/A | | | Details |
| 11/11/21 | |
Q320 | -$0.07 | -$0.05 | -$0.02 | $192.1M | $203.45M | N/A | | | Details |
| 8/11/21 | |
Q220 | $0.07 | $0.03 | +$0.04 | $202.8M | $233.24M | N/A | | | Details |
| 5/11/21 | |
Q120 | $0.19 | $0.20 | -$0.01 | $245.9M | $240.83M | N/A | | | Details |
3/9/21  |
Q419 | $0.08 | $0.06 | +$0.02 | $180.6M | $164M | N/A | | | Details | |
| 5/7/19 | |
Q319 | -$0.17 | -$0.20 | +$0.03 | $64.7M | $54.04M | N/A | | | Details |
